Menarini Group puts “Infection in focus”

Antibiotics should be used appropriately to preserve their effectiveness and slow down the emergence of new resistance.

Antibiotics save lives. When patients require them, the benefits usually outweigh the risks from side effects and the potential for the development of resistance.

As older antibiotics lose their potency due to the rise in resistant bacteria, treatments for the safe and effective management of multi-drug resistant infections decrease.

Research and development in antibiotics is associated with high failure rates and significant costs. As a result, many pharmaceutical companies have divested from this area over the years, instead choosing to focus on therapeutic areas with higher commercial returns.

As of December 2019, only 12 antibiotics were in the late stages of development of which only a handful will reach patients. In contrast, more than 700 oncological molecules are in the late phases of development. If this trend continues, the arsenal to combat resistant bacteria will soon be depleted.

In light of this situation, Menarini has taken the decision to play a role in the fight against Antimicrobial Resistance (AMR) having recently expanded its product portfolio by adding three innovative antibiotics.

To further reinforce its commitment to providing effective and innovative solutions to treat resistant infections, Menarini has become an active partner of the AMR Action Fund, along with other leading pharmaceutical companies investing more than $1 billion. This collaboration aims to bring 2 to 4 innovative antibiotics to patients by the end of 2030, bolstering the antibiotics research and development environment with industry resources, knowledge and expertise. This unique platform in collaboration with its strategic partners, will facilitate the necessary policy reforms to encourage appropriate investment in antibiotics R&D.

“Infection in Focus” has been created by Menarini with the goal of increasing awareness of AMR and fighting life-threatening bacterial infections, a rising global threat.


“Never has the threat of antimicrobial resistance been more immediate and the need for solutions more urgent,” says Dr Tedros Adhanom Ghebreyesus, Director-General of WHO.

Antibiotic resistance presents a huge threat to the achievements of modern medicine. Organ transplantation, chemotherapy and surgery such as caesarean section, become more and more dangerous without effective antibiotics to prevent and treat infections.

Numerous initiatives are underway to reduce antimicrobial resistance, but we also need countries and the pharmaceutical industry to step up and contribute with sustainable funding and innovative new medicines.” (ref. WHO website)



How is Menarini supporting the cause?

Menarini is committed to developing, commercializing and providing access to new antibiotics.

Menarini is striving against resistant infections and to reduce morbidity and mortality rates.

Menarini supports the responsible use of antibiotics through global antimicrobial stewardship programmes, based on providing the right antibiotic to the right patient at the right time.

Providing relevant stakeholders significant clinical and health-economic evidence to drive treatment decisions and pathways.



The risk of antibiotics resistance is rapidly increasing.

There is a need for urgent action: everyone must play a part.

The biopharmaceutical industry has a key role to play in the fight against antibiotic resistance.

Our current disease areas

The Global Challenge of Antimicrobial resistance (AMR)

The Global Challenge of Antimicrobial Resistance (AMR)

Antimicrobial resistance (AMR) represents a global public health threat.

Read More
The Global Challenge of Antimicrobial resistance (AMR)

The impact of AMR

The consequences of AMR on health, healthcare system and itseconomic burden are extraordinary.

Read More